Asia Pacific Anticoagulant Reversal Drug Market Size, Share, and Analysis by 2027

Historic Data: 2017-2018 | Base Year: 2019 | Forecast Period: 2020-2027

Asia Pacific Anticoagulant Reversal Drug Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product (Prothrombin Complex Concentrates, Vitamin K, Protamine, Tranexamic Acid, Idarucizumab, and AndeXXa); End User (Hospital Pharmacies, Retail Pharmacies, and Others)

Report Date : May 2021
Report Code : TIPRE00022193

Category : Life Sciences
Status : Published

Available Report Formats :
No. of Pages : 149

Page Updated: May 2021

Analysis Strategic Insights Market Drivers Regional Insights Report Scope Recent Developments FAQs

The anticoagulant reversal drug market in Asia Pacific is expected to grow from US$ 173.5 million in 2019 to US$ 444.8 million by 2027; it is estimated to grow at a CAGR of 13.2% from 2019 to 2027.

Oral anticoagulants are widely used and are highly effective in preventing thromboembolism among AFib patients. However, the use of anticoagulants may lead to bleeding in AFib patients; thus, anticoagulant reversal drugs are used to prevent bleeding. According to the report "Beyond the Burden: The Impact of Atrial Fibrillation in Asia Pacific," from Biosense Webster (part of Johnson & Johnson Medical Devices Companies), atrial fibrillation is projected to affect around 72 million people in Asia Pacific by 2050. This report was launched at the annual meeting of Asia Pacific Rhythm Society (APHRS) in Bangkok. The report studied the current state of atrial fibrillation in Asia, as well as future projections for the medical condition. The report also mentioned that the number of patients diagnosed with atrial fibrillation increases by 1.4 million every year. Thus, such high prevalence of atrial fibrillation is likely to favor the growth of the market.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the anticoagulant reversal drugs market. The Asia Pacific anticoagulant reversal drugs market is expected to grow at a good CAGR during the forecast period.

21843-img1

This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Asia Pacific Anticoagulant Reversal Drug Market Segmentation

By Product

Prothrombin Complex Concentrates
Vitamin K
Protamine
Tranexamic Acid
Idarucizumab
AndeXXa

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Others

By Country

Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Rest of Asia Pacific

Companies Mentioned

Boehringer Ingelheim International GmbH
Pfizer Inc
Octapharma AG
Fresenius Kabi AG
Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals)
CSL Limited
Grifols, S.A.
China Biologic Products, Inc
Shanghai RAAS Blood Products Co., Ltd.

Asia Pacific Anticoagulant Reversal Drug Report Scope

Report Attribute	Details
Market size in 2019	US$ 173.5 Million
Market Size by 2027	US$ 444.8 Million
Global CAGR (2019 - 2027)	13.2%
Historical Data	2017-2018
Forecast period	2020-2027
Segments Covered	By Product Prothrombin Complex Concentrates Vitamin K Protamine Tranexamic Acid Idarucizumab AndeXXa By End User Hospital Pharmacies Retail Pharmacies
Regions and Countries Covered	Asia-Pacific China India Japan Australia Rest of Asia-Pacific
Market leaders and key company profiles	Boehringer Ingelheim International GmbH Pfizer Inc Octapharma AG Fresenius Kabi AG Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals) CSL Limited Grifols, S.A. China Biologic Products, Inc Shanghai RAAS Blood Products Co., Ltd.

Research Manager

Mrinal Kerhalkar

Manager,
Market Research & Consulting

Mrinal is a seasoned research analyst with over 8 years of experience in Life Sciences Market Intelligence and Consulting. With a strategic mindset and unwavering commitment to excellence, she has built deep expertise in pharmaceutical forecasting, market opportunity assessment, and developing industry benchmarks. Her work is anchored in delivering actionable insights that empower clients to make informed strategic decisions.

Mrinal’s core strength lies in translating complex quantitative datasets into meaningful business intelligence. Her analytical acumen is instrumental in shaping go-to-market (GTM) strategies and uncovering growth opportunities across the pharmaceutical and medical device sectors. As a trusted consultant, she consistently focuses on streamlining workflow processes and establishing best practices, thereby driving innovation and operational efficiency for her clients.

What are the Asia Pacific Anticoagulant Reversal Drug Market report deliverables?

Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
PEST and SWOT Analysis
Market Size Value / Volume - Global, Regional, Country
Industry and Competitive Landscape
Excel Dataset

Recent Reports

Testimonials

I wish to appreciate your support and the professionalism you displayed in the course of attending to my request for information regarding to infectious disease IVD market in Nigeria. I appreciate your patience, your guidance, and the fact that you were willing to offer a discount, which eventually made it possible for us to close a deal. I look forward to engaging The Insight Partners in the future, all thanks to the impression you have created in me as a result of this first encounter.

DR CHIJIOKE ONYIA MANAGING DIRECTOR, PineCrest Healthcare Ltd.

The Insight Partners delivered insightful, well-structured market research with strong domain expertise. Their team was professional and responsive throughout. The user-friendly website made accessing industry reports seamless. We highly recommend them for reliable, high-quality research services

YUKIHIKO ADACHI CEO, Deep Blue, LLC.

We worked with The Insight Partners for an important market study and forecast. They gave us clear insights into opportunities and risks, which helped shape our plans. Their research was easy to use and based on solid data. It helped us make smart, confident decisions. We highly recommend them.

PIYUSH NAGPAL Sr. Vice President, High Beam Global

I requested a report on a very specific software market and the team produced the report in a few days. The information was very relevant and well presented. I then requested some changes and additions to the report. The team was again very responsive and I got the final report in less than a week.

Jean-Herve Jenn Chairman, Future Analytica

This is the first time I have purchased a market report from The Insight Partners.While I was unsure at first, I visited their web site and felt more comfortable to take the risk and purchase a market report.I am completely satisfied with the quality of the report and customer service. I had several questions and comments with the initial report, but after a couple of dialogs over email with their analyst I believe I have a report that I can use as input to our strategic planning process.Thank you so much for taking the extra time and making this a positive experience.I will definitely recommend your service to others and you will be my first call when we need further market data.

John Suzuki President and Chief Executive Officer, Board Director, BK Technologies

The Insight Partners' SCADA System Market report is comprehensive, with valuable insights on current trends and future forecasts. The team was highly professional, responsive, and supportive throughout. We are very satisfied and highly recommend their services.

Ran Kedem Partner, Reali Technologies LTDs

Reason to Buy